Relapse prevention long-acting treatment for schizophrenia
UZEDY®
UZEDY® (Risperidone LAI) was the first treatment based on BEPO® technology to receive FDA approval, initially for schizophrenia in April 2023 (one- and two-month dosing), and subsequently for Bipolar I Disorder in October 2025 (one-month dosing).
UZEDY® has been distributed since May 2023 in the United States by Teva.
UZEDY® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.
Strong differentiation thanks to BEPO®
A treatment with options
One injection every 1 or 2 months and no additional starter doses or extra pills once you start UZEDY
Small needle size
One of the smallest LAI needles used to treat schizophrenia
Injected just below the skin
Most other schizophrenia LAIs are injected into muscle
Prefilled syringe
Ready- and easy-to-use, no reconstitution needed
